Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis.

Introduction: The combination of atezolizumab/bevacizumab has emerged as an effective first-line treatment for advanced hepatocellular carcinoma (HCC). However, this therapy is potentially associated with bleeding complications, warranting a comprehensive analysis of their incidence and severity. This meta-analysis aims to synthesize available evidence from clinical trials and observational studies to quantify the prevalence of bleeding following atezolizumab/bevacizumab administration.

Electromagnetic Interference Shielding and Joule Heating Properties of Flexible, Lightweight, and Hydrophobic MXene/Nickel-Coated Polyester Fabrics Manufactured by Dip-Dry Coating and Electroless Plating.

High-performance electromagnetic interference (EMI) shielding materials with high flexibility, low density, and hydrophobic surface are crucial for modern integrated electronics and telecommunication systems in advanced industries like aerospace, military, artificial intelligence, and wearable electronics. In this study, we present flexible and hydrophobic MXene/Ni-coated polyester (PET) fabrics featuring a double-layered structure, fabricated via a facile and scalable dip-dry coating process followed by electroless nickel plating. Increasing the dip-dry coating iterations up to 10 cycles boosts the MXene loading content (∼31 wt %) and electrical conductivity (∼86 S/cm) of MXene-coated PET fabrics, while maintaining constant porosity (∼95%).

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.

: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC). : We would like to introduce the cases of two patients who underwent bevacizumab reduction or discontinuation when VB occurred after atezolizumab/bevacizumab. : VB occurred in two patients who showed good tumor response after atezolizumab/bevacizumab treatment, and all VBs were successfully treated with endoscopic variceal ligations.

Complications of immunotherapy in advanced hepatocellular carcinoma.

Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period.

A control system of a negative hydrogen ion sources by using an EPICS-based proportional-integral-derivative.

We have developed an EPICS-based control system for a multicusp negative ion source based on a VME IOC software, a sequencer controlling a closed proportional integral (PI) loop, and an interlock. The PI loop was tuned by a step input voltage, and tuning gains of the proportion and integral have been determined. The PI logics, developed by using standard proportional-integral-derivative records, can control the arc current within +/-1% of a given set value.

Fast triggers for a proton injector at PEFP.

A fast timing system has been developed to control transistor transistor logic (TTL) trigger signals which are used to extract the pulsed proton beam from an ion source with the precision of less than submicro seconds. The system has been designed to set a delay and duty of the pulses, respectively, and prohibit the beam pulse by an external interlock signal. The system is based on VME which is composed of VME CPU and fast I/O boards with fan-out modules.